# A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

> **NCT06329141** · PHASE2 · RECRUITING · sponsor: **Glaceum** · enrollment: 90 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Vutiglabridin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06329141
- **Lead sponsor:** Glaceum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329141, "A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06329141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*